|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer.
|
31630846 |
2020 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibitors of nuclear poly(ADP-ribose) polymerase (PARP) enzymes (e.g., PARP-1) have improved clinical outcomes in ovarian cancer, especially in patients with BRCA1/2 gene mutations or additional homologous recombination (HR) DNA repair pathway deficiencies.
|
31594824 |
2020 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanisms of PARP inhibitor resistance in ovarian cancer.
|
31815769 |
2020 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Inhibitors of PARP, which is a DNA damage repair enzyme, have been approved for use in BRCA mutated cancers like breast and ovary cancer.
|
31303961 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, 3 new PARP inhibitors (olaparib, rucaparib, niraparib) have been approved for use in ovarian cancer, with different indications as maintenance therapy or treatment of recurrence.
|
31117037 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
GnRH-R-Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition.
|
30926640 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors in ovarian cancer.
|
30543930 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the past few years, the advent of PARP inhibitors has been a revolution in the management of ovarian cancer.
|
31335830 |
2019 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
|
30551885 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors (PARPi) represent a major advance in the treatment of ovarian cancer associated with defects in homologous recombination DNA repair (HRR), primarily due to mutations in BRCA genes.
|
30342021 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Success for First-Line PARP Inhibition in Ovarian Cancer.
|
31591108 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors have been widely tested in clinical trials, especially for the treatment of breast cancer and ovarian cancer, and were shown to be highly successful.
|
29684820 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several PARP inhibitors, which are oral drugs and generally well tolerated, have now received FDA approval for various ovarian cancer and breast cancer indications.
|
30177437 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer.
|
30353044 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
|
30540933 |
2018 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
|
29567272 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
|
29352572 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
|
29871906 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we review the current therapeutic settings combining anti-angiogenesis inhibitors with chemotherapy, PARP inhibitors or immune checkpoint blockers, focusing on ovarian cancer as tumor model.
|
29703482 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP Inhibitors in Ovarian Cancer.
|
29512470 |
2018 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer.
|
29644491 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
|
29464354 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors, such as Olaparib, have advanced the treatment of ovarian cancer by providing patients with an effective and molecularly-targeted maintenance therapy.
|
30555227 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides mechanistic rationales for combining CNDAC with PARP inhibitors, platinum compounds and taxanes in ovarian cancer lacking BRCA1/2 function.
|
29189915 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Originally presumed to inhibit DNA repair, PARP inhibitors that have recently been approved by the FDA for the treatment of advanced ovarian cancer also act as DNA damaging agents by inducing PARP-DNA complexes.
|
28643177 |
2017 |